Related Experiment Videos
[Various methods of using lincomycin for treating acute and chronic hematogenic osteomyelitis in children]
Abstract:
Comparative data on the treatment of 209 children with acute and chronic hematogenic osteomyelitis are presented; 128 patients hospitalized before 1974 were treated with antibiotics, mainly penicillin and streptomycin without sensitivity testing. From 1974 81 children were treated with lincomycin; 80 per cent of the isolates were sensitive to this antibiotic. In lincomycin therapy the method of electrophoresis on the disease focus, intrabone administration of the drug and administration of the drug into the bone cavity together with the blood clot during surgical interventions in cases with chronic hematogenic osteomyelitis were used. A marked decrease in the rate of the chronic forms of the disease was registered (from 77.2 to 8.8 per cent).
Insights
Lincomycin therapy significantly reduced chronic hematogenic osteomyelitis in children. This antibiotic, used with advanced methods, proved more effective than older treatments, decreasing chronic cases from 77.2% to 8.8%.
Area of Science:
- Pediatric Infectious Diseases
- Orthopedic Surgery
- Pharmacology
Background:
- Hematogenic osteomyelitis is a serious bone infection in children.
- Traditional antibiotic treatments (penicillin, streptomycin) lacked sensitivity testing and showed limitations.
- A need existed for more effective treatment strategies for pediatric osteomyelitis.
Purpose of the Study:
- To compare the efficacy of lincomycin therapy versus older antibiotic regimens for acute and chronic hematogenic osteomyelitis in children.
- To evaluate the impact of specific lincomycin administration methods on treatment outcomes.
- To assess the reduction in chronic forms of the disease following lincomycin implementation.
Main Methods:
- Retrospective comparison of treatment outcomes in 209 children with hematogenic osteomyelitis.
- Group 1 (pre-1974): 128 patients treated with penicillin and streptomycin without sensitivity testing.
- Group 2 (post-1974): 81 patients treated with lincomycin, including electrophoresis, intrabone administration, and administration into bone cavities during surgery for chronic cases.
Main Results:
- Lincomycin demonstrated high sensitivity (80%) among bacterial isolates.
- A significant decrease in the incidence of chronic hematogenic osteomyelitis was observed, dropping from 77.2% to 8.8%.
- Specific methods like intrabone administration of lincomycin were employed in chronic cases.
Conclusions:
- Lincomycin therapy, especially with targeted administration methods, is highly effective in treating pediatric hematogenic osteomyelitis.
- The shift to lincomycin therapy led to a substantial reduction in the chronicity of the disease.
- Sensitivity testing and advanced drug delivery methods are crucial for optimizing osteomyelitis treatment outcomes in children.